Cannabinoids reduce symptoms of Tourette’s syndrome
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Currently, the treatment of Tourette's syndrome (TS) is unsatisfactory. Therefore, there is expanding interest in new therapeutical strategies. Anecdotal reports suggested that the use of cannabis might improve not only tics, but also behavioural problems in patients with TS. A single-dose, cross-over study in 12 patients, as well as a 6-week, randomised trial in 24 patients, demonstrated that Delta9-tetrahydrocannabinol (THC), the most psychoactive ingredient of cannabis, reduces tics in TS patients. No serious adverse effects occurred and no impairment on neuropsychological performance was observed. If well-established drugs either fail to improve tics or cause significant adverse effects, in adult patients, therapy with Delta9-THC should be tried. At present, it remains unclear whether herbal cannabis, different natural or synthetic cannabinoid CB1-receptor agonists or agents that interfere with the inactivation of endocannabinoids, may have the best adverse effect profile in TS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321 · cited 3×
“Within the basal ganglia, CB1 receptors are particularly prominent in the globus pallidus (GP) and substantia nigra pars reticulata – the indirect and direct output pathways [44].”
BackgroundAnthony, J. C., Warner, L. A., & Kessler, R. C. (1994) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.2.3.244 · Cited by 1,341
Glass, M., Faull, R. L. M., & Dragunow, M. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00428-9 · Cited by 1,052 · cited 1×
“In the CNS, the highest densities of CB1 receptors were found in the basal ganglia, cerebellum and hippocampus [44,45].”
BackgroundCannabis use and mental health in young people: cohort study.
Patton, G. C., Coffey, C., Carlin, J. B., Degenhardt, L., Lynskey, M., & Hall, W. (2002) · BMJ · doi:10.1136/bmj.325.7374.1195 · Cited by 997
Cannabis dependence and psychotic symptoms in young people
FERGUSSON, D. M., HORWOOD, L. J., & SWAIN-CAMPBELL, N. R. (2003) · Psychological Medicine · doi:10.1017/s0033291702006402 · Cited by 415 · cited 1×
“, severe and refractory epilepsy or severe vomiting during antineoplastic treatment) because there is evidence that frequent cannabis use in young people is associated with increased rates of psychotic symptoms, depression and anxiety [33,34].”
BackgroundCannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: A pilot study
Sieradzan, K. A., Fox, S. H., Hill, M., Dick, J. P. R., Crossman, A. R., & Brotchie, J. M. (2001) · Neurology · doi:10.1212/wnl.57.11.2108 · Cited by 349 · cited 1×
“In humans, it has been shown that nabilone, a classical synthetic THC analogue, ameliorates levodopa-induced dyskinesia in PD [56].”
BackgroundMuller-Vahl, K. R., Schneider, U., Prevedel, H., Theloe, K., Kolbe, H., Daldrup, T., & Emrich, H. M. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0417 · Cited by 270
Treatment of Tourette's Syndrome with Δ9-Tetrahydrocannabinol (THC): A Randomized Crossover Trial
Müller-Vahl, K., Schneider, U., Koblenz, A., Jöbges, M., Kolbe, H., Daldrup, T., & Emrich, H. (2002) · Pharmacopsychiatry · doi:10.1055/s-2002-25028 · Cited by 256
Self-citationDopamine transporter binding in Gilles de la Tourette syndrome
Müller-Vahl, K. R., Berding, G., Brücke, T., Kolbe, H., Meyer, G. J., Hundeshagen, H., Dengler, R., Knapp, W. H., & Emrich, H. M. (2000) · Journal of Neurology · doi:10.1007/pl00007806 · Cited by 95 · cited 1×
“From neuroimaging studies, it is suggested that presynaptic dopamine transporter abnormalities are involved in the pathophysiology of TS [50,51].”
BackgroundSelf-citation
Cited by
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
Cannabinoids in medicine: A review of their therapeutic potential
Ben Amar, M. (2006) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2006.02.001 · Cited by 543
Ligresti, A., De Petrocellis, L., & Di Marzo, V. (2016) · Physiological Reviews · doi:10.1152/physrev.00002.2016 · Cited by 469
Synthesis and biological activity of vicinal diaryl-substituted 1H-imidazoles
Bellina, F., Cauteruccio, S., & Rossi, R. (2007) · Tetrahedron · doi:10.1016/j.tet.2007.02.075 · Cited by 254
Bilbao, A., & Spanagel, R. (2022) · BMC Medicine · doi:10.1186/s12916-022-02459-1 · Cited by 181
Metadata
- Authors
- Müller-Vahl, K. R.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa UK Limited
- Published
- 2003-10
- Volume
- 4
- Issue
- 10
- Pages
- 1717-1725
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2151332369
- Cited by
- 74
- References
- 9
- FWCI
- 4.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cannabinoids reduce symptoms of Tourette’s syndrome. https://app.cochat.ai/papers/10.1517/14656566.4.10.1717
- The paper
- Müller-Vahl, K. R. (2003). Cannabinoids reduce symptoms of Tourette’s syndrome. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656566.4.10.1717
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.